drugset / Trial / NCT05317858
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immune checkpoint inhibitors.
Timeline
- Start
- 2022-08-12
- Primary completion
- 2027-06-01
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Atezolizumab | Monoclonal antibody | — | — |
| Background | Cemiplimab | Monoclonal antibody | — | — |
| Background | Iptilimumab | Unknown | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |